Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ART0380 |
Synonyms | |
Therapy Description |
ART0380 inhibits ATR activity leading to decreased phopshorylation of Chk1, which may result in impaired DNA damage repair, induction of apoptosis in tumor cells, and antitumor activity (NCI Drug Dictionary, (Ann Oncol 34 (2023): S475-S476). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ART0380 | ART-0380|ART 0380 | ATR Inhibitor 16 | ART0380 inhibits ATR activity leading to decreased phopshorylation of Chk1, which may result in impaired DNA damage repair, induction of apoptosis in tumor cells, and antitumor activity (NCI Drug Dictionary, (Ann Oncol 34 (2023): S475-S476). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM dec exp ATM inact mut | mantle cell lymphoma | predicted - sensitive | ART0380 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ART0380 inhibited cell growth of a mantle cell lymphoma cell line with an inactivating ATM mutation and decreased Atm expression in culture and inhibited tumor growth in a cell line xenograft model (PMID: 38416404). | 38416404 |
ATM S214Pfs*16 | colorectal cancer | sensitive | ART0380 | Preclinical - Pdx | Actionable | In a preclinical study, ART0380 inhibited tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring ATM S214Pfs*16 (PMID: 38416404). | 38416404 |
ATM E473* ATM loss | lung adenocarcinoma | sensitive | ART0380 | Preclinical - Pdx | Actionable | In a preclinical study, ART0380 induced tumor regression in a lung adenocarcinoma patient-derived xenograft (PDX) model harboring ATM E473* with loss of Atm expression (PMID: 38416404). | 38416404 |
ATM S214Ffs*40 ATM loss | colorectal cancer | sensitive | ART0380 | Preclinical - Pdx | Actionable | In a preclinical study, ART0380 inhibited tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring ATM S214Ffs*40 with loss of Atm expression (PMID: 38416404). | 38416404 |
ATM M779I | colorectal cancer | sensitive | ART0380 | Preclinical - Pdx | Actionable | In a preclinical study, ART0380 inhibited tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring ATM M779I (PMID: 38416404). | 38416404 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05798611 | Phase II | ART0380 | Study of ART0380 in Advanced/Metastatic Solid Tumors Patients (ARTIST) | Recruiting | USA | FRA | ESP | 0 |
NCT04657068 | Phase Ib/II | ART0380 + Gemcitabine ART0380 Gemcitabine | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |